BE887518A - Cartothioates d'androstanes - Google Patents

Cartothioates d'androstanes

Info

Publication number
BE887518A
BE887518A BE0/203794A BE203794A BE887518A BE 887518 A BE887518 A BE 887518A BE 0/203794 A BE0/203794 A BE 0/203794A BE 203794 A BE203794 A BE 203794A BE 887518 A BE887518 A BE 887518A
Authority
BE
Belgium
Prior art keywords
cartothioates
androstan
androstan cartothioates
Prior art date
Application number
BE0/203794A
Other languages
English (en)
French (fr)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BE887518A publication Critical patent/BE887518A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE0/203794A 1980-02-15 1981-02-13 Cartothioates d'androstanes BE887518A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8005174 1980-02-15

Publications (1)

Publication Number Publication Date
BE887518A true BE887518A (fr) 1981-08-13

Family

ID=10511390

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/203794A BE887518A (fr) 1980-02-15 1981-02-13 Cartothioates d'androstanes

Country Status (8)

Country Link
US (1) US4335121A (en, 2012)
JP (1) JPS56138200A (en, 2012)
BE (1) BE887518A (en, 2012)
CA (1) CA1201114A (en, 2012)
EC (1) ECSP941097A (en, 2012)
PH (1) PH24267A (en, 2012)
ZA (1) ZA81976B (en, 2012)
ZW (1) ZW18081A1 (en, 2012)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861765A (en) * 1985-06-26 1989-08-29 Jouveinal 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them
GB8630913D0 (en) * 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
JPH0231703A (ja) * 1988-07-22 1990-02-01 Sukai:Kk 口紅付きリップブラシ
US5208226A (en) * 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
UA26230A (uk) * 1990-03-02 1999-07-19 Глексо Груп Лімітед Іhгалятор для спільhого використаhhя з лікувальhим блоком і лікувальhий блок
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
CA2126244C (en) 1991-12-18 2000-09-26 Robert K. Schultz Suspension aerosol formulations
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
GB9507768D0 (en) * 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
EP1769819A3 (en) 1995-04-14 2013-05-22 GlaxoSmithKline LLC Metered dose inhaler for fluticasone propionate
SK139197A3 (en) * 1995-04-14 1998-04-08 Glaxo Wellcome Inc Metered dose inhaler for beclomethasone dipropionate
RO119116B1 (ro) 1995-04-14 2004-04-30 Glaxo Wellcome Inc. Inhalator pentru dozarea salmeterolului
AP791A (en) * 1995-04-14 1999-12-17 Glaxo Wellcome Inc Metered dose inhaler for albuterol.
US5981517A (en) * 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US20030103906A1 (en) * 1997-10-14 2003-06-05 Smithkline Beecham Corporation Metered dose inhaler having internal surfaces coated with fluorocarbon polymer
US5993782A (en) * 1998-04-28 1999-11-30 Gardner; Conrad O. Therapeutic method for reversing hyposmia in a human patient
US20020133032A1 (en) * 2000-02-25 2002-09-19 Jufang Barkalow Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) * 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
CA2417825C (en) * 2000-08-05 2008-07-22 Glaxo Group Limited 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl)oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
WO2002024552A2 (en) 2000-09-18 2002-03-28 Glaxo Group Limited Coated can for a metered dose inhaler
BR0208012A (pt) * 2001-03-20 2004-03-02 Glaxo Group Ltd Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
MY137522A (en) * 2001-04-30 2009-02-27 Glaxo Group Ltd Novel anti-inflammatory androstane derivatives.
WO2002100879A1 (en) * 2001-06-12 2002-12-19 Glaxo Group Limited Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
AU2002321884A1 (en) * 2001-08-03 2003-02-24 Smithkline Beecham Corporation A method for preparing fluticasone derivatives
GB0202563D0 (en) * 2002-02-04 2002-03-20 Glaxo Group Ltd Process
GB0202564D0 (en) * 2002-02-04 2002-03-20 Glaxo Group Ltd Process
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
AU2003263575A1 (en) * 2002-06-20 2004-01-06 Sun Pharmaceutical Industries Limited Convenient synthesis of s-fluoromethyl 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha- methyl-17alpha-propionyloxy-3-oxoandrosta-1, 4-diene-17beta-carbothioate
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
JP2006511297A (ja) * 2002-12-18 2006-04-06 グラクソ　グループ　リミテッド ベント型マウスピースを有する投薬システム
CA2530680A1 (en) * 2003-04-04 2004-10-14 Alpharma Aps Process for the preparation of steroidal carbothioic acid derivatives and intermediates
EP1620083A2 (en) * 2003-04-18 2006-02-01 Pharmacia & Upjohn Company LLC Combination therapies
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
CA2537185A1 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
AU2004272077A1 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
EP1526139A1 (en) * 2003-10-24 2005-04-27 S.N.I.F.F. Italia S.P.A. A process for preparing highly pure androstane 17-beta-carboxylic acids and androstane 17-beta-carbothioic acid fluoromethyl esters
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
CA2547782A1 (en) * 2003-12-03 2005-06-16 Microdrug Ag Medical product containing tiotropium
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
US20060009435A1 (en) * 2004-06-23 2006-01-12 Joseph Kaspi Synthesis and powder preparation of fluticasone propionate
CA2575376A1 (en) * 2004-07-26 2006-02-02 Chemagis Ltd. Novel crystalline forms of 6alpha, 9alpha-difluoro-11beta hydroxy-16alpha-methyl-3-oxo-17alpha-propionyloxy-androsta-1,4-diene-17beta-carboxylic acid and processes for preparationthereof
PT103202B (pt) 2004-10-19 2011-01-27 Hovione Farmaciencia S A Processo para a esterificação de um ácido carbotiótico
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
CN100560598C (zh) 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
JP5216589B2 (ja) 2005-09-02 2013-06-19 ニコックス エス エイ ステロイドのニトロオキシ誘導体
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20090054382A1 (en) * 2005-10-19 2009-02-26 Abhijit Ray Compositions of phosphodiesterase type iv inhibitors
JP2009512676A (ja) 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ムスカリン性受容体アンタゴニストの医薬組成物
EP1957080A4 (en) * 2005-12-09 2013-10-09 Fougera Pharmaceuticals Inc TOPICAL GLUCOCORTICOSTEROID FORMULATIONS
AR059216A1 (es) * 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
WO2007144668A2 (en) * 2006-06-14 2007-12-21 Generics [Uk] Limited Process for the preparation of s-fluoromethyl-6, 9 -difluoro-11 -hydroxy-16 -methyl-17-propionyloxy-3-oxo-androsta-1,4-diene-17 -carbothioate and intermediates
AU2013202835B2 (en) * 2006-06-14 2015-11-12 Generics [Uk] Limited Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1, 4-diene-17-carbothioate and intermediates
GB0612027D0 (en) * 2006-06-16 2006-07-26 Glaxo Group Ltd Novel process
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
PL2046787T3 (pl) 2006-08-01 2011-10-31 Glaxo Group Ltd Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4
AU2007298549A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
MX2009008582A (es) 2007-02-11 2009-10-30 Map Pharmaceuticals Inc Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios.
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
CN103497185A (zh) * 2007-03-14 2014-01-08 兰贝克赛实验室有限公司 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
NO331891B1 (no) * 2007-03-20 2012-04-30 Clavis Pharma Asa Kjemiske forbindelser, et farmasoytisk preparat inneholdende slike forbindelser, samt anvendelse derav for behandling av kreft, inflammasjon og KOLS
US20080318915A1 (en) * 2007-06-20 2008-12-25 Protia, Llc Deuterium-enriched fluticasone propionate
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
US8796248B2 (en) 2007-10-05 2014-08-05 Nektar Therapeutics Oligomer-corticosteroid conjugates
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US7935837B2 (en) * 2008-04-30 2011-05-03 Corum Inc. Process for synthesis of androstane 17-β carbothioic acid and relative compounds thereof
WO2010025236A1 (en) * 2008-08-27 2010-03-04 Alexander Goldin Composition and method for treating colds
WO2010097248A1 (en) 2009-01-13 2010-09-02 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP2435024B1 (en) * 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
RS57595B1 (sr) 2009-10-01 2018-11-30 Adare Pharmaceuticals Inc Kortikosteroidne kompozicije za oralnu administraciju
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
WO2011093813A1 (en) 2010-01-28 2011-08-04 Mahmut Bilgic Dry powder pharmaceutical composition comprising tiotropium and fluticasone
TR201000685A2 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik preparatlar.
WO2011093811A2 (en) 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical preparations comprising formoterol and fluticasone
TR201000733A2 (tr) 2010-02-02 2011-08-22 Bi̇lgi̇ç Mahmut Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
EP2563364A1 (en) 2010-04-26 2013-03-06 Mahmut Bilgic Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
EP2611821A2 (en) 2010-09-01 2013-07-10 Cadila Healthcare Limited Process for preparing fluticasone propionate/furoate
ES2626702T3 (es) 2010-10-27 2017-07-25 Hovione Inter Limited Reactivos electrófilos para monohalometilación, su preparación y usos
CN102558273B (zh) * 2010-12-14 2014-07-02 浙江省天台县奥锐特药业有限公司 氟替卡松糠酸酯的制备方法
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
EP2683716A1 (en) 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
US20150165037A1 (en) 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
US20150224197A1 (en) 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
MX361286B (es) 2013-03-15 2018-12-03 Pearl Therapeutics Inc Métodos y sistemas para el acondicionamiento de materiales cristalinos de partículas.
MX2015016283A (es) 2013-05-28 2016-03-11 Sun Pharma Advanced Res Co Ltd METODOS PARA TRATAR AFECCIONES INFLAMATORIAS UTILIZANDO S-[4-(3-FLUORO-3-METILBUTIRILOXI) BUT-2-INIL] 6A, 9A-DIFLUORO-17A- (FURAN-2-IL) CARBONILOXI-11ß-HIDROXI-16A - METIL-3-OXOANDROSTA-1,4-DIEN-17ß - CARBOTIOATO.
US20160129207A1 (en) 2013-06-17 2016-05-12 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation composition filling method
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
US9796750B2 (en) 2014-02-07 2017-10-24 Mylan Laboratories Ltd. Process for the purification of fluticasone propionate using a ketone solvent and water as anti-solvent
US9303060B1 (en) 2014-10-03 2016-04-05 Amphaster Pharmaceuticals, Inc. Methods of preparing intermediate of fluticasone propionate
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN110698530A (zh) * 2019-10-30 2020-01-17 山东赛托生物科技股份有限公司 一种丙酸氟替卡松的合成方法
CR20240063A (es) 2021-07-09 2024-04-25 Astrazeneca Pharmaceuticals Lp Composiciones, métodos y sistemas para la administración de fármacos en aerosol
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636010A (en) * 1968-12-23 1972-01-18 Ciba Geigy Corp Esters of steroid-17-carboxylic acids
US3828080A (en) * 1972-01-20 1974-08-06 Glaxo Lab Ltd Androstane-17beta-carboxylic acids and processes for the preparation thereof
US4093721A (en) * 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
US4188385A (en) * 1978-04-05 1980-02-12 Syntex (U.S.A.) Inc. Thioetianic acid derivatives

Also Published As

Publication number Publication date
ZW18081A1 (en) 1981-10-21
PH24267A (en) 1990-05-29
US4335121A (en) 1982-06-15
JPS6337120B2 (en, 2012) 1988-07-22
CA1201114A (en) 1986-02-25
ECSP941097A (es) 1995-01-16
JPS56138200A (en) 1981-10-28
ZA81976B (en) 1982-07-28

Similar Documents

Publication Publication Date Title
BE887518A (fr) Cartothioates d'androstanes
BE875773A (nl) 2'deoxy-5-(halogeenvinyl)-uridines
TR21767A (tr) N-fenilsulfonil-n'-pirimidinil-ve-triazinilureler
BE879683A (fr) Strijkpapierbekledingsmassa's met hoge vaste-stofconcentratie
LT2397B (lt) Dantu iklotu sudetis
DK163246C (da) 4'-keto-n-trifluoracetyldaunorubicin
BE876123A (fr) Installation d'ascenseur
ATE202T1 (de) 2-cycloalkyl-pyrimidin(5)
BE876795A (fr) Installation d'ensachage
DE3141464A1 (de) "kopiergeraet"
FR2427285B1 (fr) Installation d'ascenseur
BE876388A (fr) Installation d'ascenseur
LU81071A1 (fr) Vitrai 12
BE896957A (fr) Vecteur d'expression
IT1157288B (it) Agenti anti-obesita'
BE893837A (fr) Vecteurs d'expression
SU1179923A3 (ru) "cпocoб пoлучehия aзoлилпehtehпpoизboдhыx"
FI790141A7 (fi) 2 6-dinitrobensenaminer
IT1124914B (it) Procedimento per prevenire l'imbrattamento di elettrodi
BE883955A (fr) "limnimetre"
BE885171A (fr) Installation d'acenseur
NO822578L (no) Tilhengerfeste
BE883954A (fr) "spanningsverzorgingsschakeling"
RO84326A (ro) Compresor de agent frigorigen
IT7866310A0 (it) Tiche'

Legal Events

Date Code Title Description
CCPA Application for a supplementary protection certificate

Free format text: 094C0001

CCPV Grant of a supplementary protection certificate

Free format text: 094C0001, EXPIRES 20050308

RE20 Patent expired

Owner name: GLAXO GROUP LTD

Effective date: 20010213

CCRE Expiry of a supplementary protection certificate

Free format text: PRODUCT NAME FLUTICASONE PROPIONATE (MICRONISE); NAT. REG. NO/DATE 276 S 660 F 11/19931202; FIRST REG GB/PL0045/0153 19900308

Spc suppl protection certif: 94C0001

Filing date: 19951031

Expiry date: 20010213

Extension date: 20050308

CCRE Expiry of a supplementary protection certificate

Free format text: PRODUCT NAME: FLUTICASONE PROPIONATE (MICRONISE); NAT. REG.: 276 S 660 F 11 19931202;FIRST REG.: GBPL0045/0153 19900308

Spc suppl protection certif: 94C0001

Filing date: 19940119

Expiry date: 20010213

Extension date: 20050308